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Abstract
Background: The aim of the study is to carry out a cost-effectiveness analysis of three different interventions to promote
the uptake of screening for cervical cancer in general practice in the county of Valles Occidental, Barcelona, Spain.
Methods: Women aged from 30 to 70 years (n = 15,965) were asked to attend a general practice to be screened. They
were randomly allocated to one of four groups: no intervention group (NIG); one group where women received an
invitation letter to participate in the screening (IG1); one group where women received an invitation letter and
informative leaflet (IG2); and one group where women received an invitation letter, an informative leaflet and a phone
call reminder (IG3). Clinical effectiveness was measured as the percentage increase in screening coverage. A cost-
effectiveness analysis was performed from the perspective of the public health system with a time horizon of three to
five years – the duration of the randomised controlled clinical trial. In addition, a deterministic sensitivity analysis was
performed. Results are presented according to different age groups.
Results: The incremental cost-effectiveness ratio (ICER) for the most cost-effective intervention, IG1, compared with
opportunistic screening was € 2.78 per 1% increase in the screening coverage. The age interval with the worst results in
terms of efficiency was women aged < 40 years.
Conclusions: In a population like Catalonia, with around 2 million women aged 30 to 70 years and assuming that 40%
of these women were not attending general practice to be screened for cervical cancer, the implementation of an
intervention to increase screening coverage which consists of sending a letter would cost on average less than € 490
for every 1000 women.
Trial registration: ClinicalTrials.gov Identifier: NCT01373723.
Keywords: Cost-effectiveness, Population screening, Cervical cancer, Increase coverage
Background
In Spain, both cervical cancer incidence and survival
have remained stable over the past few years [1, 2]. The
global estimate of the age-adjusted incidence rate of in-
vasive cervical cancer was 7.8 per 100,000 woman-years
in 2012, [3] which means that Spain is in the low-mid
range of European countries (3.6–28.6 per 100.000
woman-years). In the Autonomous Region of Catalonia,
the truncated incidence rate is 16.1 per 100,000 woman-
years for those aged from 35 to 64 years, meaning the
risk of developing a cervical cancer is one in 106 women
who have lived to the age of 75 years old [4]. The five
year net survival in Spain was 65.2 for women diagnosed
during 2005–2009 and comparable with or even higher
than most developed countries. Despite these relatively
positive data, cervical cancer is still a public health con-
cern because it is largely preventable and also due to the
high cost of screening and treatment of cervical lesions.
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Cancer cost the EU € 126 billion in 2009, with health
care accounting for € 51 billion (40%) [5]. In Australia,
which has lower cervical cancer incidence and higher
survival than Spain, the total cost of the screening
programme was estimated to be € 130.4 million (2015)
and the treatment cost accounted for approximately
one-third of the total (€ 109.8 million [2015]) [6].
In Spain, cytological screening for cervical cancer is
largely opportunistic with some variations in the proto-
col according to region [7]. Eighty percent of the cases
of cervical cancer in Catalonia did not undergo a previ-
ous cytology exam during the 10 years prior to diagnosis
[8]. In Catalonia, the protocol, which was revised and
modified by the Oncology Director Plan and the Catalan
Institute of Oncology in 2006, incorporated the estab-
lishment of triennial periodicity of cytology exams in
women from 25 to 65 years of age and of the HPV test
in women from 40 to 65 years of age with no prior cy-
tology exam within the previous five years or with a cy-
tology exam carried out longer than five years previous,
abnormal cytology results (no specified atypical squa-
mous lesions), and women with post-conisation control
of intraepithelial lesions. An increase in screening cover-
age through interventions promoting the uptake of
screening should be a priority objective for health care
authorities if cervical cancer cases are to be reduced and
women who do not periodically have a cytology exam
are to be identified.
According to a systematic review of the Cochrane col-
laboration, [9] evaluating interventions to stimulate the
participation of women in the screening of this disease,
invitations and educational interventions seem to be the
most effective ways to increase participation in screening
programmes. In addition, there is sufficient evidence of
increasing coverage when using individualised informa-
tion directed at the target population, especially with
systems for call-recall (that is, SMS, email, phone calls)
[10, 11]. Everett et al in 2011 encouraged providing trials
to further support strategies to increase coverage [9].
This would facilitate earlier action in detecting pre-
malignant lesions, helping to reduce the incidence of in-
vasive cancer and their costs. Therefore, there is a need
to evaluate strategies to increase the screening popula-
tion coverage for efficiency. This will allow decision-
makers to make better informed decisions on which pre-
ventive programmes to conduct in Spain. The CRI-
CERVA study (Acera et al.: Increasing cervical cancer
screening coverage: a randomised, community-based
clinical trial, accepted and forthcoming) is a cluster clin-
ical trial that assigned one of three interventions to the
target population registered in the Cerdanyola SAP area
in Barcelona. A total of 32,858 women residing in the
study area, aged 30 to 70 years and with no record of a
cervical cytology exam during the past 3.5 years, were
selected. The study included four arms: three interven-
tions (a personalised invitation letter, an additional in-
formative leaflet, and an additional personalised phone
call) and a control group (based on spontaneous
demand).
The aim of this study is to perform a cost-effectiveness
analysis alongside the CRICERVA clinical trial, (Acera et
al.: Increasing cervical cancer screening coverage: a ran-
domised, community-based clinical trial, accepted and
forthcoming) of three different active interventions to
promote the uptake of screening for cervical cancer in
general practice. An orientative protocol of this eco-
nomic evaluation was first published in 2011 [12].
Methods
CRICERVA project
The CRICERVA Study was a community-based cluster
clinical trial with four arms assigned into groups and
performed in a predefined geographical area as defined
by the Primary Health Care Service (SAP) Cerdanyola,
in the metropolitan belt of Barcelona, Spain, and was
subdivided into five areas, four of which were included
in this study. SAP Cerdanyola covers a population of
120,293 individuals over the age of 14 years. The female
population aged between 30–70 ascribed to the study
areas were as follows, Study Area 1: N = 8968; Study
Area 2: N = 8169; Study Area 3: N = 11,027; and Study
Area 4: N = 4694. For the study’s purposes, the eligibility
criteria included women from 30 to 70 years of age
whose general practitioner was ascribed to the SAP Cer-
danyola area, who were residents of the area for more
than six months, and who had no record in the medical
registry of screening for cervical cancer in the prior
3.5 years. This resulted in the identification of 15,965 out
of 32,858 (48.58%) women. The selected women were
clustered randomly and contacted according to their allo-
cated arm. When personal contact was established, they
were asked to answer interview questions. Additional file 1
presents the questionnaire developed for this study. The
interview allowed us to identify those women appropriate
for screening and invite them for testing.
The sample size was calculated based on the detection
of a difference in effectiveness compared with the NIG.
It was calculated by multiplying the size of a simple ran-
domised design by the design effect or factor of inflation.
For the simple randomised design, accepting an alpha
risk of 0.05 and a beta risk of 0.20 in a bilateral contrast,
59 subjects were required in the first group and 59 in
the second group to detect a difference of greater than
or equal to 28.4% in the screening coverage of 41.6% in
the NIG. The lost follow-up rate was estimated at 20%.
The calculation of the sample was performed using the
Granmo 5.2 computer programme for Windows. Con-
sidering an intraclass correlation coefficient of 0.05 and
Trapero-Bertran et al. BMC Public Health  (2017) 17:194 Page 2 of 8
a mean number of 3500 women from 30 to 70 years of
age with incorrect screening by Basic Health Care Area,
the design effect was 176 and, thus, 20,768 women with
incorrect screenings were required. Women eligible for
screening were verbally informed about the screening
procedures and the significance of the results. Women
were excluded if they had a hysterectomy, a current his-
tory of cervical intraepithelial lesions, carcinoma in situ
and cervical uterine cancer, and a diagnosis of HIV or
immunosuppression. All members of the targeted popu-
lation were invited to participate. AP Cerdanyola was di-
vided into five Basic Health Care Centres (BHCC), four
of which were included in the study.
The cluster unit was each of the four BHCCs. Each of
the four participating BHCCs were randomly assigned to
one study arm. The follow-up period of this trial finished
when the diagnosis of each screening visit was com-
pleted. After completing the recruitment of the interven-
tion groups, we characterised the women in the NIG in
terms of screening practices and, if appropriate, invited
them to be screened.
The interventions evaluated were 1) a personalised
invitation letter to participate in the screening signed
by the patient’s primary care physician and profes-
sionals of the corresponding Public Health Center
(IG1); 2) the same letter of invitation sent in IG1 as
well as an informative leaflet on the prevailing screen-
ing of cervical cancer (IG2); and 3) the same inter-
vention as the one performed in IG2, complemented
with a phone call three days prior to the appointment
indicated in the letter of invitation as a reminder of
the visit (IG3). These three interventions were com-
pared to the NIG in which participants could avail of
current opportunistic screening. There was one com-
mon action in the three different interventions, which
was scientifically validated as effective, and consisted
of a personalised invitation letter sent by the primary
health care professionals including a fixed appoint-
ment with the GP to get a cytology test. Two other
different interventions (informative leaflet and re-
minder call) were also included to evaluate ap-
proaches for which there are few studies assessing the
effectiveness of attendance of screening programmes.
Women were distributed as follows: 4197 patients to
IG1; 3601 to IG2; 6088 to IG3; and 2079 to the NIG.
Sociodemographic characteristics of the population
are shown in Table 3. From these, 1377 (47%) women
in IG1, 1258 (48%) in IG2, and 1628 (40%) in IG3
did not meet the appointments. In addition, 1248
women in IG1, 976 in IG2, and 2064 in IG3 were ex-
cluded because of adequate screening in the private
system, a hysterectomy, a cervical disease, a change of
address, or death. These numbers add up to 1578
screening visits in IG1, 1367 visits in IG2, and 2396
visits in IG3. Hence, the average total number of pa-
tients who responded to all the interventions was ap-
proximately 56%. The highest response rate was
observed in the IG2 group (58.3%), followed by IG1
(55.9%), and IG3 (53.7%). The youngest (younger than
40 years) and the elderly (70 years or older) were the
groups least responsive to any intervention. Table 1
shows the target population; women invited to par-
ticipate in this study because the last screening hap-
pened three and a half years prior; women who were
contacted and were willing to attend the GP visit;
and the number of women who finally attended the
GP visit.
The Ethical Committee of the Institute of Research in
Primary Care (IDIAP Jordi Gol) in Catalonia, Spain, ap-
proved this study, as well as the CRICERVA study
Table 1 Population included in the CRICERVA project
Population IG1 (letter) IG2 (letter + leaflet) IG3 (letter + leaflet
+ phone call)
Target population
< 40 3251 2847 3799
40-49 2444 2146 2812
50-59 1784 1900 2406
≥ 60 1489 1276 2010
Total 8968 8169 11027
Poorly screened
populationa
< 40 1113 948 1449
40-49 1224 974 1750
50-59 798 754 1260
≥ 60 1062 925 1629
Total 4197 3601 6088
Answer to the
interventionb
< 40 879 862 1079
40-49 861 683 1050
50-59 611 589 932
≥ 60 604 491 963
Total 2955 2625 4024
Women screened
by the interventionc
< 40 449 392 576
40-49 512 381 665
50-59 314 318 584
≥ 60 303 276 571
Total 1578 1367 2396
aInvited to participate because last screening was more than three and a half
years ago
bThose women who are contacted through any of the interventions and are
willing to attend the GP visit
cNumber of women who finally attend th GP visit
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(Acera et al.: Increasing cervical cancer screening cover-
age: a randomised, community-based clinical trial, ac-
cepted and forthcoming).
Health outcome and cost data
Effectiveness data were provided from the CRIVERVA
project (Acera et al.: Increasing cervical cancer screening
coverage: a randomised, community-based clinical trial,
accepted and forthcoming). The outcome measure was
the increase percentage in the screening coverage over
42 months. The acceptance rate was highest among the
IG3 group (23%), followed by IG1 (18.6%), while IG2
had the lowest average success rate (17.4%).
The analysis was performed from the Public Health
System perspective and, therefore, only direct health
care costs were included. All available management costs
per unit were adapted from Diaz et al., [13] whereas
strict costs from interventions were calculated from the
Reproductive and Sexual Health Primary Care Unit
(ASSIR) [14] (Table 2). Management costs included
15 min for a nurse or midwife visit, a cytology kit for
taking the smear, and an HPV test. Inflation rates were
applied to management costs in 2014 [15]. These three
costs were considered in the three interventions and also
for the NIG, because all women – opportunistically or
not – coming to the Basic Health Care Area (BHCA)
were incurring these costs. However, the costs for each
of the interventions were different. The IG1 included
the costs of a letter, postage, and two minutes of an offi-
cer’s time to prepare the letter for posting. The IG2 in-
cluded the costs of IG1, plus the cost of a leaflet and
just a few more seconds of the officer’s time to prepare
this mail-out. Finally, the IG3 included not only the
costs of IG2, but the cost of a reminder call lasting one
to five minutes and the extra officer time spent carrying
this out. Costs are expressed in €, 2014.
Analysis
The time horizon of the analysis was 3.5 years, the dur-
ation of the randomised controlled clinical trial. Costs
and effects were not discounted because the results are
reported over the trial period. A cost-effectiveness ana-
lysis of the different interventions was performed using
incremental cost-effectiveness ratios (ICERs) [16].
ICERs were calculated as the additional benefit to be
gained in € per effectiveness unit (1% coverage) from
one alternative compared to another.
Difference in Costs Between Two Interventions
Difference in the % of Screening Coverage
Between Two Interventions
All results were presented according to different age
groups (<40; 40–49; 50–59; ≥60). In order to measure
the uncertainty of results, a deterministic univariate sen-
sitivity analysis was performed to examine the effect of
the uncertainty on the effectiveness parameter.
Results
Table 3 describes the sociodemographic and behavioural
characteristics of women interviewed in each intervention
group. Table 4 presents the cost-effectiveness analysis of
the intervention groups. The ICERs’ competing choices
approach shows that, including women of all ages, IG2 is
strongly dominated because it is more expensive and less
effective than IG1. IG1 costs € 2.78 per 1% increase in
coverage compared to an opportunistic screening and IG3
costs € 13.73 per 1% increase in coverage more than an
opportunistic screening, making IG1 more cost-effective.
In the comparisons with the next best alternative, IG3
costs € 60.73 per 1% increase in coverage more than IG1.
Therefore, for women of all ages, IG1 is the most cost-
effective alternative. Results differ in scale across age
groups, but not conceptually and IG2 is always strongly
dominated by IG1 (see Table 5). ICERs for IG1, compared
with opportunistic screening or the next best alternative
are lower than € 4 per 1% increase in coverage for all age
groups. IG2 costs € 103.85 per 1% increase in coverage
more than IG1 for women ≥60 years; for the rest of the
age groups, IG2 compared to IG1 is either a dominated or
more expensive alternative. The age group obtaining worst
results in terms of efficiency was women aged <40 years,
although ICERs are still quite economically sensible (€
3.55 per 1% increase in coverage for IG1 and € 177.86 per
1% increase in coverage for IG3). Therefore, consistently
sending a letter seems to be the most cost-effective inter-
vention for women of all ages.
Table 2 Management costs
Interventions Costs(€ 2014)
NIG Includes one visit with 15 min of a nurse/midwife (35.64€), one citology (21.78€) and one HPV test (28.71€) (Total: 86.13€)
IG1 Cost of the no intervention plus a letter and its posting (0.16€) and the office time (0.33€) (Total: 86.62€)
IG2 Cost of the no intervention plus a letter and its posting (0.16€) plus a leaflet and its posting (1€),and the officer time (0.33€ + 0.35€)
(Total: 87.97€)
IG3 Cost of the no intervention plus a letter and its posting (0.16€) plus a leaflet and its posting (1€),a reminding call (0.30€) and the
officer time (0.33€ + 0.35€ + 0.83€) (Total: 89.10€)
Source: References [12] and (Acera et al.: Increasing cervical cancer screening coverage: a randomised, community-based clinical trial, accepted and forthcoming)
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Sensitivity analysis
When the increase of coverage is reduced by 50%, results
remain the same in terms of efficiency ranking, with the
option of sending a letter (IG1) being the most cost-
effective intervention compared with doing nothing. Even
if the final coverage was decreased by 75% of the results
experienced in the CRICERVA study, cost-effectiveness
results would remain, showing the robustness of this ana-
lysis and the low values obtained for ICERs of each inter-
vention compared with doing nothing.
Discussion
This economic evaluation assessed whether the increase
in participation rates of screening for cervical cancer
compensates for the costs incurred from different inter-
ventions. Observing our results, if a universal strategy is
applied for all age groups, the preventive intervention of
sending a letter for an appointment is the most efficient
with a cost of around € 3 per 1% coverage, followed by
sending a letter with a leaflet and a reminder call with a
cost of € 61 per 1% coverage. The intervention of send-
ing a letter with a leaflet (IG2) is more expensive and
less effective than only sending a letter (IG1). Results by
age are consistent; the intervention of sending a letter
costs less than € 4 per 1% coverage and sending a letter
with a leaflet and a reminder call costs between € 2 and
€ 178, depending on the age; the older the women, the
more cost-effective this intervention.
Table 3 Sociodemographic and behavioural characteristics of women interviewed
Characteristic No
Intervention
Group (NIG)
Intervention groups Total P
Letter (IG1) Letter + leaflet (IG2) Letter + leaflet + phone call (IG3)
Interviewed 857 807 848 1011 3523
Age, mean (SD) 50.8 (12.7) 49.5 (12.1) 50.0 (12.4) 51.1 (12.0) 50.4 (12.3) 0.018
Spanish nationality 827 (96.5%) 744 (92.2%) 768 (90.7%) 900 (89.1%) 3239 (92.0) <0.001
Educational level
None 43 (5.1%) 82 (11.9%) 64 (9.5%) 71 (8.0%) 260 (8.4%) <0.001
Primary 504 (30.1%) 380 (27.5%) 377(28.0%) 423 (23.8%) 1684 (27.2%)
High School/ University 291(17.3%) 229(16.5%) 231(17.2%) 395(22.2%) 1146(18.5%)
Marital status-married 594 (70.3%) 518 (74.6%) 513 (76.5%) 666 (74.7) 2291 (73.9%) 0.037
Number of children
0 93 (11.0%) 97 (14.0%) 74 (11.0%) 114 (12.8%) 379 (12.2%) 0.002
1-2 443 (52.5%) 404 (58.4%) 394 (58.5%) 524 (58.9%) 1765 (57.0%)
> 2 308 (36.5%) 191 (27.6%) 205 (30.5%) 251 (28.2%) 955 (30.8%)
Lag time since last Pap screening
1-3 years 417 (48.7%) 348 (43.8%) 369 (44.6%) 421 (42.1%) 1555 (44.7%) 0.002
4-6 years 322 (37.6%) 282 (35.5%) 294 (35.6%) 391 (39.1%) 1289 (37.1%)
never 117 (13.7%) 164 (20.7%) 164 (19.8%) 189 (18.9%) 634 (18.2%)
Reasons for non-attendance to screening for women with no previous Pap
Fear and dislike 23 (19.8%) 65 (41.1%) 68 (42.2%) 73 (40.3%) 229 (37.2%) <0.001
Uninformed 91 (78.4%) 84 (53.2%) 80 (49.7%) 98 (54.1%) 353 (57.3%)
Other 2 (1.7%) 9 (5.7%) 13 (8.1%) 10 (5.5%) 34 (5.5%)
The questionnaires completed for the intervention groups were carried out during routine medical visits. For the non-intervention group the questionnaires were
completed at the end of the study by appropriately trained personnel during a telephone call
Source: (Acera et al.: Increasing cervical cancer screening coverage: a randomised, community-based clinical trial, accepted and forthcoming)
Table 4 Cost-effectiveness analysis results over the CRICERVA study for all ages
Group Cost Incremental coverage (%) ICER(1) ICER(2)
No intervention (NIG) 86.13€
IG1 (letter) 86.62€ 17.6% 2.78 2.78 (IG1 vs NIG)
IG2 (letter + leaflet) 87.97€ 16.7% 11.02 Dominated (IG2 vs IG1)
IG3 (letter + leaflet + phone call) 89.11€ 21.7% 13.73 60.73 (IG3 vs IG1)
(1) Incremental cost-effectiveness ratio of each intervention group compared with the no intervention (opportunistic screening) group expressed as € per
1% coverage
(2) Incremental cost-effectiveness ratio of one intervention compared with the next least expensive strategy expressed as € per 1% coverage
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The cost-effectiveness of interventions to promote cer-
vical cancer have already been assessed in another study
[17]. Although not all the interventions were the same
as the ones analysed in this paper, the letter was com-
mon to all of them and the comparator was the oppor-
tunistic screening. In that paper, the most cost-effective
intervention was to remind a doctor to offer a smear
during a consultation; however, the authors were operat-
ing in a relatively disadvantaged area and populations
are not comparable. However, another paper reinforces
the results we obtained in this study [18]. The authors
state that telephone contact with women who have
abstained from cervical cancer screening for a long time
increases participation and leads to a significant increase
in detection of atypical smears. Other authors also sup-
port the idea that contacting women through a postal
reminder is as effective as, and less expensive than, a
telephone call [19]. In our study, there was no interven-
tion involving an email, but IG3 comprised a telephone
call and was the least cost-effective intervention com-
pared to opportunistic screening.
According to some authors, there are large variations
in cervical cancer screening policies, coverage, and qual-
ity of screening across Europe [20]. As assessed by other
studies, the recommendations of the Council of the
European Union (EU) on organised population-based
screening for cervical cancer have not yet been fulfilled
[21]. The European cervical cancer screening guidelines
were prepared for all European countries (not just for
EU members), but many of them failed in implementa-
tion [22]. Spain has opportunistic screening imple-
mented by regions and the age range is established
between 30 and 65 years [20]. Decisions on the target
age group and frequency of screening are usually made
at the national level; however, continued unavailability of
population-based, systematically organised screening
programmes to women who may benefit from screening
remains the major obstacle in the control of cervical
cancer in Europe. Some authors claim that the evalu-
ation of screening activity related to cervical cancer
using cohort studies designs among screening popula-
tions are proceeding in some countries, but results are
not available yet [23]. Others recently stated that a shift
from opportunistic to organised screening is imperative
to optimise the cost and impact of screening, but no evi-
dence on cost-effectiveness has been published for this
type of study [24]. This paper tries to bridge these gaps
by providing information on efficiency of different inter-
ventions in order to start building a nationally organised
screening programme. However, the available evidence
supports the hypothesis that while organised population
screening programmes are successful in increasing over-
all participation rates, they may not per se substantially
reduce social inequalities [25].
With regard to the factors influencing participation in
screening, some authors have suggested the following:
the absence of population programmes; low sensitisa-
tion with respect to preventive attitudes in cohorts of
elderly women; and health care overload in primary
care centres [10, 26].
This economic evaluation just covers diagnosis on the
illness pathway; however, this will influence the cost-
effectiveness of the whole cervical cancer pathway.
Therefore, there is a need to build a model for the nat-
ural history of cervical cancer for Spain, such as the one
built for Germany [27] and study the cost-effectiveness
of the whole pathway, accounting for organised cervical
cancer screening programmes.
In a population like Catalonia with around two million
women aged 30–70 years and assuming that 40%
(800,000) of these women have not been screened for
the last 3 years, the implementation of an intervention
to increase screening coverage in 1% implies that the
government would need to pay € 2.78 for a 1% of in-
crease in coverage. In this study, the NIG (n = 428
Table 5 Cost-effectiveness analysis results over the CRICERVA
study by age group
Age Incremental
coverage (%)
ICER(1) ICER(2)
Women < 40
No intervention (NIG)
IG1 (letter) 13.8% 3.55 3.55 (IG1 vs NIG)
IG2 (letter + leaflet) 13.8% 13.33 more expensive
(IG2 vs IG1)
IG3 (letter + leaflet
+ phone call)
15.2% 19.60 177.86 (IG3 vs IG1)
Women 40-49
No intervention (NIG)
IG1 (letter) 20.9% 2.34 2.34 (IG1 vs NIG)
IG2 (letter + leaflet) 17.8% 10.34 Dominated (IG2 vs IG1)
IG3 (letter + leaflet
+ phone call)
23.6% 12.63 92.22 (IG3 vs IG1)
Women 50-59
No intervention (NIG)
IG1 (letter) 17.6% 2.78 2.78 (IG1 vs NIG)
IG2 (letter + leaflet) 16.7% 11.02 Dominated (IG2 vs IG1)
IG3 (letter + leaflet
+ phone call)
24.3% 12.26 37.16 (IG3 vs IG1)
Women ≥ 60
No intervention (NIG)
IG1 (letter) 20.3% 2.41 2.41 (IG1 vs NIG)
IG2 (letter + leaflet) 21.6% 8.52 103.85 (IG2 vs IG1)
IG3 (letter + leaflet
+ phone call)
28.4% 10.49 16.76 (IG3 vs IG1)
(1) Incremental cost-effectiveness ratio of each intervention group com-
pared with the no intervention (opportunistic screening) group
expressed as € per 1% coverage
(2) Incremental cost-effectiveness ratio of one intervention compared
with the next least expensive strategy expressed as € per 1% coverage
Trapero-Bertran et al. BMC Public Health  (2017) 17:194 Page 6 of 8
women, spontaneous demand) cost the Catalonian gov-
ernment €36,864; the women attending the screening
because of the letter (IG1, n = 1578) cost € 136,683
(which increased the coverage of the screened popula-
tion by 17.6%); the women attending the screening be-
cause of the letter and the leaflet (IG2, n = 1367) cost €
120,255 (which increased the coverage of the screened
population by only 16.7%); and the women attending the
screening because of the letter, leaflet, and phone call
(IG3, n = 2396) cost € 213,484 (which increased the
coverage of the screened population by 21.7%). However,
if all women were contacted using IG1, the most cost-
effective strategy, the screening of the 5669 women would
have cost € 491,049; therefore, the Catalonian government
would have saved € 16,237. Obviously, the higher the
number of women screened, the higher the saving. Thus,
to test 5669 women costs € 507,286 in total.
Conclusion
The ICER for the most cost-effective intervention, IG1,
compared with opportunistic screening was € 2.78 per 1%
increase in the screening coverage; IG2 and IG3 have more
efficiency for the elderly group (≥60). Sending a letter
would cost on average around € 490 for every 1000 women.
The age interval with the worst results in terms of efficiency
was for women aged <40 years. This analysis encourages in-
cluding this intervention in the national policy on screening
to prevent cervical cancer, because this would complement
the opportunistic system; until then, screening cannot be
said to be organised at a national level.
Additional file
Additional file 1: Cricerva Study Questionnaire. Description of data:
Interview guide developed during the study. (PDF 36 kb)
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